What is erectile dysfunction?
Erectile dysfunction is the inability to achieve or maintain an erection during sexual intercourse. Most cases of erectile dysfunction are associated with vascular, neurological, psychological and hormonal disorders. The use of certain medications can also be a cause.
The evaluation usually includes screening for underlying disorders and measuring testosterone levels
Tyra 20 of the medicines used are phosphodiesterase inhibitors, which have proven effective in treating erectile dysfunction patients.
The scientific name for Tyra is: Tadalafil
Tadalafil pills treat premature ejaculation and erectile dysfunction in men by secreting nitric oxide from the body during sexual intercourse, relaxing and expanding muscles, thus increasing blood flow naturally in the penis, in addition to inhibiting the effect of the phosphodiesterase 5 enzyme responsible for breaking down the substance responsible for relaxing the muscles of the penis.
The effect of tadalafil pills
Tadalafil works in 30 minutes and lasts up to 36 hours
Characteristics of Tyra 20
Tyra 20 is the second generation of selective PDE5 inhibitors
Tyra 20 has the ability to improve erectile function for up to 36 hours
Tyra 20 is safer with fewer side effects
Tyra 20 improves overall satisfaction in men with mild, moderate, and severe erectile dysfunction
Tyra 20 takes effect within 30 minutes of taking the pill
If you suffer from heart disease, please consult your doctor or pharmacist before starting to take TYRA 20
References
- Porst, H. (2002). IC351 (tadala_l, Cialis): update on clinical experience. International journal of impotence research, 14 (1).
- Hedelin, H., & Ströberg, P. (2005). Treatment for Erectile Dysfunction Based on Patient-Reported Outcomes. Drugs, 65(16), 2245-2251.
- Montorsi, F., Kuritzky, L., Sadovsky, R., Fredlund, P., & Cordell, W. H. (2005). Frequently asked questions about tadala_l for treating men with erectile dysfunction. Journal of Men’s Health and Gender, 2(1), 141-157
- Rosen, R. C., Shabsigh, R., Kuritzky, L., Wang, W. C., & Sides, G. D. (2005). The e_cacy of tadala_l in improving sexual satisfaction and overall satisfaction in men with mild, moderate, and severe erectile dysfunction: a retrospective pooled
analysis of data from randomized, placebo-controlled clinical trials. Current medical research and opinion, 21(11), 1701-1709.
- Hatzichristou, D., Haro, J. M., Martin-Morales, A., Von Keitz, A., Riley, A., Bertsch, J., … & EDOS Group. (2007). Patterns of switching phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction: results from the Erectile
Dysfunction Observational Study. International journal of clinical practice, 61(11), 1850-1862.
- Conaglen, H. M., & Conaglen, J. V. (2008). Investigating women’s preference for sildena_l or tadala_l use by their partners with erectile dysfunction: The partners’ preference study. The journal of sexual medicine, 5(5), 1198-1207.